




1st Quarter Financial Results for FYE/Mar 2010

**Terumo Corporation
July 30, 2009**

Sales (by Region)

(Unit: Billion yen)




Sales (by Product Group)


(Unit: Billion yen)

Mar. 2009 Q1 Mar. 2010 Q1

() : local currency basis




Gross Profit (%)



FYE/Mar. 2009 Q1: 54.3% → FYE/Mar. 2010 Q1 : 53.6%

SG&A Expenses

(Unit: Billion yen)



SG&A. expense ratio to sales improved by 1.1pt

Japan:

- R&D was reinforced
- A growth of retirement benefit expense was offset by a reduction of expense

Outside of Japan :

- Reduced across the Group, and improved due to a favorable impact of foreign exchange

Forecast :

Forecast for the 1st Half Revised Upward

	FYE/Mar. 2010 Q1 Results	FYE/Mar.2010 1st Half Year Forecast	(Billion yen) FYE/Mar.2010 Forecast
Net Sales	77.5	154.0	315.0
Operating Income	16.5 (21.3%)	28.0 (18.2%)	56.0 (17.8%)
Ordinary Income	16.9 (21.9%)	28.0 (18.2%)	56.0 (17.8%)
Net Income	10.8 (14.0%)	18.0 (11.7%)	37.5 (11.9%)
Average exchange rate	1US\$ 97 yen 1EUR 133 yen	Q2 90 yen Q2 120 yen	95 yen 125 yen




Topics

- Performance trend update
- Growth potential of interventional systems business
- Others

Impact Limited Despite Slow Sales of Large Equipment

Overseas sales of large-sized equipment for cardiac surgery


(billion yen)




Large-sized equipment for cardiac surgery:
Heart-lung machine
“Sarns Advanced Perfusion System 1”

Big Buyer China Robust Among Emerging Markets

(US\$ Mil.)



Unique Growth Potential Driving Entire Business Expansion




(conceptual image)


“3 Basic Items” That Always Grow

Competitive quality that induces demand shifts to Terumo products


- Growth on market expansion



- Growth on field diversification




Extending Portfolio of Guide Wire Products



Sales Growing on Products Offering Healthcare Economy Benefit


PTCA balloon catheter product lineup and sales volume (Japan)

No. of units (Thousand)



New Field Becoming New Growth Pillar


Sales of coils for use in treating neuro aneurysms



Coil Market Set to Continue Expanding

Trends in the neuro aneurysm treatment market

No. of cases worldwide
(Thousand)



(Based on surveys by Terumo)

Pursuing Synergies Since The Acquisition

Trend in neuro aneurysm treatment


[Access devices]
Terumo technology

- 3 basic items
- Micro wire
- Guiding catheter

+


[Treatment coils]
MicroVention technology

- Barecoil
- Hydrocoil
- HydroSoft



Coils for abdominal peripheral arteries

Other Topics 1) U.S.



(Sales of catheter products in the U.S. market)


Other Topics 2) Thailand

Leveraging the Terumo brand to offer a full lineup of products

Hospitals: pursuing a safety strategy

Entry into the diabetes treatment business

The no.1 presence in interventional systems (Terumo share:40% Exclude DES)





Summary

The strong yen has been a big problem, but we are gradually overcoming it.

We have had some success in boosting our profitability.


We have made a smooth start in achieving our goal of increasing revenues and profits.

Reference

Factor of Change of Sales and Operating Profit

[Sales]


Q1 Mar.2009: 77.8 bln yen → Q1 Mar. 2010: 77.5 bln yen - 0.3 bln yen



[Operating Income]

Q1 Mar.2010: 16.2 bln yen → Q1 Mar. 2010: 16.5 bln yen +3 bln yen

**Increase of amount / Improving
product mix line and others**




Reference

(Unit: millions of yen)

	Mar. 2009 1st Quarter	Mar. 2010 1st Quarter	Mar. 2010 Forecast
R&D Expense	3,772	3,922	19,000
Depreciation Expense	4,641	4,481	21,000
Investment in Plant and Equipment	3,235	5,157	23,000
Free Cash Flow	-10,237	493	
Shareholder's Equity Per Share (Yen)	72.27	56.94	197.47

“Tazuna,” New PTCA Balloon Catheter Suitable for TRI Launched




* What's TRI...

In TRI (Transradial Coronary Intervention), a balloon catheter is inserted from a micro wrist artery to approach the coronary artery.

It imposes as little physical burden on patients as they can walk soon after the operation, and facilitates outpatient surgery.

Requisites for penetration of TRI procedures





IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: kouhou_terumo01@terumo.co.jp

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this booklet is partly derived from our own independent research.